CD38 PRODUCT COLLABORATION AGREEMENTCd38 Product Collaboration Agreement • October 29th, 2019 • I-Mab • Pharmaceutical preparations • Hong Kong
Contract Type FiledOctober 29th, 2019 Company Industry JurisdictionThis CD38 PRODUCT COLLABORATION AGREEMENT (the “Agreement”) is entered into on January 22, 2018 (the “Effective Date”) between I-Mab, a company organized and existing under the laws of Cayman Islands and having its registered address at P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205 Cayman Islands (“I-Mab”), and EVEREST MEDICINES LIMITED, a company organized and existing under the laws of Cayman Islands and having its registered address at 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands (“Everest”). Everest and I-Mab are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CD38 PRODUCT COLLABORATION AGREEMENTCd38 Product Collaboration Agreement • September 5th, 2019 • I-Mab • Pharmaceutical preparations • Hong Kong
Contract Type FiledSeptember 5th, 2019 Company Industry JurisdictionThis CD38 PRODUCT COLLABORATION AGREEMENT (the “Agreement”) is entered into on January 22, 2018 (the “Effective Date”) between I-Mab, a company organized and existing under the laws of Cayman Islands and having its registered address at *** (“I-Mab”), and EVEREST MEDICINES LIMITED, a company organized and existing under the laws of Cayman Islands and having its registered address at *** (“Everest”). Everest and I-Mab are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”